CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)
Clinical trials for CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) explained in plain language.
Never miss a new study
Get alerted when new CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) trials appear
Sign up with your email to follow new studies for CUTANEOUS LUPUS ERYTHEMATOSUS (CLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill could tame skin lupus flares
Disease control Not yet recruitingThis study tests an oral drug called ICP-488 for people with cutaneous lupus erythematosus (CLE), a condition that causes painful skin rashes and lesions. About 105 adults aged 18 to 75 will receive either the drug or a placebo to see if it reduces skin disease activity over 16 w…
Matched conditions: CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)
Phase: PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New lupus drug candidate enters human safety testing
Disease control Not yet recruitingThis study tests a new drug called HC022 in 32 people with lupus (SLE or CLE). The main goal is to see if it is safe and how the body handles it. Participants will receive multiple doses of the drug or a placebo. This is an early-stage trial, so it focuses on safety and dosing, n…
Matched conditions: CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)
Phase: PHASE1 • Sponsor: HC Biopharma Inc. • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New drug S-4321 tested for multiple autoimmune conditions
Disease control Not yet recruitingThis early-phase study tests an experimental drug called S-4321 in 24 adults with autoimmune diseases like rheumatoid arthritis, psoriasis, lupus, or eczema. The main goal is to check safety and how the body processes the drug. Researchers will also look at early signs of effecti…
Matched conditions: CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)
Phase: PHASE1 • Sponsor: Seismic Therapeutic AU Pty Ltd • Aim: Disease control
Last updated May 15, 2026 11:53 UTC